Effectiveness and Safety of Mobile Artificial Cervical Vertebrae Replacement for Patients With Cervical Spondylosis

April 7, 2021 updated by: Qiang Yin, Xi'an International Medical Center Hospital

Effectiveness and Safety of Mobile Artificial Cervical Vertebrae Replacement for Patients With Cervical Spondylosis: Study Protocol for a Prospective, Non-randomized Controlled, Clinical Trial

The research team designed an artificial cervical joint prosthesis suitable for subtotal resection of the lower cervical vertebral body. Previous studies regarding cadaver and animal experiments have found that this artificial joint not only retains the normal range of physiological motion of the joint, but also has good stability. Preliminary studies have shown that the designed joints are sufficiently safe and stable. The titanium materials for joints have been verified for their toxicology in long-term clinical trials and have been monitored under relevant national testing agencies in China.

Study Overview

Detailed Description

Artificial cervical disc technology has achieved certain clinical effects in the treatment of single-segment lesions of the lower cervical spine. However, simple artificial cervical disc replacement is only applicable for single-segment disc herniation, but not for two adjacent cervical segmental lesions, concurrent with vertebral hyperplasia and ossification of the posterior longitudinal ligament in the cervical spine. Traditional vertebral corpectomy and bone graft fusion can reduce the mobility of the cervical spine. Therefore, non-fusion fixation for such diseases has been a key issue to improve the efficacy of surgical treatments.

To this end, the research team designed an artificial cervical joint prosthesis suitable for subtotal resection of the lower cervical vertebral body. Previous studies regarding cadaver and animal experiments have found that this artificial joint not only retains the normal range of physiological motion of the joint, but also has good stability. Preliminary studies have shown that the designed joints are sufficiently safe and stable. The titanium materials for joints have been verified for their toxicology in long-term clinical trials and have been monitored under relevant national testing agencies in China.

To serve clinical patients faster and ensure that the trial design is safe, this study is designed to observe the effectiveness and safety of mobile artificial cervical vertebrae replacement for patients with cervical spondylosis.

Study Type

Interventional

Enrollment (Anticipated)

40

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • Shaanxi
      • Xi'an, Shaanxi, China, 710100
        • Xi'an International Medical Center Hospital
        • Contact:
        • Principal Investigator:
          • Xijing He, MD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 70 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • (1)Age: 18-70 years, irrespective of sex;
  • (2)For mobile artificial cervical vertebrae replacement, patients with cervical spondylosis who are planned to undergo anterior cervical corpectomy and resection of two adjacent intervertebral discs;
  • (3)For anterior cervical corpectomy and fusion, patients with cervical spondylosis who are planned to undergo anterior cervical corpectomy and resection of two adjacent intervertebral discs;

Exclusion Criteria:

  • (1) Patients who have participated in other clinical studies 3 months before the inception of the study;
  • (2) Abnormalities in liver and kidney functions (aspartate aminotransferase, alanine aminotransferase, blood creatinine and urea nitrogen levels are 1.5 times higher than normal);
  • (3) Obvious abnormalities in the blood system;
  • (4) Abuse of drugs or ethanol;
  • (5) Patients who have brain disorders, abnormal judging ability, or cannot cooperate with the observer;
  • (6) Coronary heart disease or severe kidney disease;
  • (7) Severe metabolic diseases and endocrine diseases that are out of drug control;
  • (8) Pregnant and lactating women and couples who are about to become pregnant in the near future;
  • (9) Severe lung diseases such as asthma and lung dysfunction;
  • (10) Immunodeficiency;
  • (11) Single-segment intervertebral disc herniation or compression;
  • (12) 3 or more vertebral segments herniated or spinal cord compression due to ligament ossification;
  • (13) Active infection (systemic or local cervical spine) or a history of local cervical spine infection;
  • (14) A history of anterior cervical surgery;
  • (15) Patients with a need for posterior surgical treatments, with severe arthritis of the cervical spine joint process, and with spinal cord compression on the back;
  • (16) Severe osteoporosis;
  • (17) Cervical vertebra deformity;
  • (18) A history of ossification of the posterior longitudinal ligament of the cervical spine, ankylosing spondylitis, and heterotopic ossification;
  • (19) Severe cervical spine instability or trauma to the posterior structure of the cervical spine, and cervical spondylolisthesis;
  • (20) Abnormal soft tissues anterior to the cervical spine (tracheal or esophageal malformations, and a history of radiotherapy), and obesity;
  • (21) Allergy to prosthetic materials;
  • (22) Patients who have tumors that cannot be completely resected and patients who are predicted to suffer prosthetic loosening during survival time;
  • (23) Other contraindications for surgery.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Non-Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Trial group
20 patients with cervical spondylosis undergoing mobile artificial cervical vertebrae replacement
  1. Position: The patient is in a supine position with the neck hyperextended, ensuring his/her neck and shoulders in a stable and neutral position before surgery and the cervical spine in a "physiological" curvature position.
  2. Anesthesia: General anesthesia via oral tracheal intubation.
  3. Surgical approach: Anterior cervical spine approach through the space between the visceral sheath and the vascular sheath.
  4. Surgical method: Two intervertebral discs with adjacent lesions and part of the vertebral body between them will be removed. A curette is used to carefully strike off the annulus fibrosus and cartilage on the surface of the adjacent upper and lower endplates. Intraoperatively, the midlines of the segment and the vertebra to be replaced should be mapped out. When decompression, the midline for decompression should not be deviated from the planned midlines.
Other Names:
  • Trial group
Experimental: Control group
20 patients with cervical spondylosis undergoing anterior cervical corpectomy and fusion
  1. Position: The patient is in a supine position with the neck hyperextended.
  2. Anesthesia: General anesthesia via oral tracheal intubation.
  3. Surgical approach: Anterior cervical spine approach through the space between the visceral sheath and the vascular sheath.
  4. Surgical method: Two intervertebral discs with adjacent lesions and part of the vertebrae between them will be removed. A curette will be used to carefully strike off the annulus fibrosus and cartilage on the surface of the adjacent upper and lower endplates. The removed vertebral bone will be trimmed into cancellous bone particles and filled in a cervical titanium cage with an appropriate size. The titanium cage will be implanted into the vertebral space, and fixed with adjacent vertebrae using anterior cervical titanium plates and screws.
Other Names:
  • Control group

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Cervical joint range of motion at 6 months after operation
Time Frame: 6 months after operation
Testing methods for cervical joint mobility include: Cervical joint range of motion in all directions will be accurately obtained through an in vitro infrared measurement after artificial joint replacement (joint range in °).
6 months after operation

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Cervical fusion rate at 3 to 6 months after operation
Time Frame: 3 to 6 months after operation

A successful fusion is assessed according to Brantigan and Steffee's imaging rating scale:

Suspicious bone fusion: bone bridge formation in the entire fusion area with a density at least similar to postoperative data, and no light-transmitting band between the grafted bone and the vertebral body; Strong fusion: the fused bone in the fusion area is more mature and dense as shown on postoperative images. A sclerosis zone between the grafted bone and the vertebral body indicates the fusion, but there is no interface between the grafted bone and the vertebral body, and the mature bone trabecula forms a bone bridge. The bone spurs on the anterior side of the vertebral body will be absorbed, and the bone graft in the intervertebral space will move forward until the facet joints are fused. Fusion rate = (number of successfully fused patients/total number of patients) × 100% (Fusion rate in percentage).

3 to 6 months after operation
Cervical joint range of motion at 7 days to 3 months after operation
Time Frame: 3 to 6 months after operation

Testing methods for cervical joint mobility include

  1. X-ray: The mobility of the cervical spine during flexion and extension, lateral flexion, and rotation;
  2. Coda Motion, an internationally advanced joint mobility measuring instrument of the experimental unit, will be used to measure cervical spine mobility;
  3. Cervical joint range of motion in all directions will be accurately obtained through an in vitro infrared measurement after artificial joint replacement.
3 to 6 months after operation
Japanese Orthopaedic Association (JOA) scores at 7 days to 6 months after operation
Time Frame: 7 days to 6 months after operation
JOA scoring involves upper limb motor function (4 points), lower limb motor function (4 points), sensation (6 points) and bladder function (3 points). The higher score indicates the better motor function
7 days to 6 months after operation
Neck Disability Index (NDI) scores at 7 days to 6 months after operation
Time Frame: 7 days to 6 months after operation
NDI is mainly used for assessing cervical spine function. The higher score indicates the severer cervical spine dysfunction.
7 days to 6 months after operation
Visual analogue scale (VAS) scores at 7 days to 6 months after operation
Time Frame: 7 days to 6 months after operation
VAS is mainly used for pain assessment. The higher score indicate the severer pain.
7 days to 6 months after operation
CT images of the cervical spine at 7 days postoperatively
Time Frame: 7 days after operation
CT images of the cervical spine are used to evaluate the implantation of the artificial cervical joint.
7 days after operation
X-ray of the cervical spine at 7 days to 6 months after operation
Time Frame: 7 days to 6 months after operation
X-ray of the cervical spine is used for evaluating the morphology of the implanted cervical joint morphology.
7 days to 6 months after operation

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
The incidence of adverse events at 7 days to 6 months after operation.
Time Frame: 7 days to 6 months after operation
Adverse events include implant shedding, displacement, joint loosening, fracture, prolapse, infection, and heterotopic ossification. The incidence of adverse events = (number of patients with adverse events/total number of patients)×100%.
7 days to 6 months after operation

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Xijing He, MD, Xi'an International Medical Center Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Anticipated)

June 1, 2021

Primary Completion (Anticipated)

November 1, 2022

Study Completion (Anticipated)

November 1, 2022

Study Registration Dates

First Submitted

March 17, 2021

First Submitted That Met QC Criteria

March 19, 2021

First Posted (Actual)

March 24, 2021

Study Record Updates

Last Update Posted (Actual)

April 12, 2021

Last Update Submitted That Met QC Criteria

April 7, 2021

Last Verified

April 1, 2021

More Information

Terms related to this study

Other Study ID Numbers

  • XianInternationalMCH_HXJ_02

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cervical Spondylosis

Clinical Trials on mobile artificial cervical vertebrae replacement

3
Subscribe